Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Stock analysts at William Blair issued their Q1 2026 earnings per share estimates for Pyxis Oncology in a report released on Friday, August 15th. William Blair analyst A. Hsieh forecasts that the company will post earnings of ($0.36) per share for the quarter. The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology's Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.35) EPS.
A number of other analysts also recently issued reports on the company. Zacks Research raised Pyxis Oncology from a "strong sell" rating to a "hold" rating in a report on Monday. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Tuesday. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $8.67.
Read Our Latest Report on PYXS
Pyxis Oncology Trading Up 2.7%
NASDAQ:PYXS traded up $0.0350 during midday trading on Monday, reaching $1.3550. The company had a trading volume of 305,816 shares, compared to its average volume of 546,627. The firm has a market capitalization of $84.04 million, a price-to-earnings ratio of -0.85 and a beta of 1.13. The stock's fifty day simple moving average is $1.16 and its 200-day simple moving average is $1.15. Pyxis Oncology has a 12-month low of $0.8332 and a 12-month high of $5.3899.
Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million during the quarter.
Institutional Trading of Pyxis Oncology
Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE increased its position in Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock valued at $84,000 after acquiring an additional 9,062 shares during the period. Barclays PLC increased its position in Pyxis Oncology by 20.2% in the 4th quarter. Barclays PLC now owns 77,013 shares of the company's stock valued at $121,000 after acquiring an additional 12,924 shares during the period. ProShare Advisors LLC acquired a new position in Pyxis Oncology in the 4th quarter valued at about $26,000. Jane Street Group LLC increased its position in Pyxis Oncology by 36.6% in the 4th quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock valued at $106,000 after acquiring an additional 18,128 shares during the period. Finally, Ameriprise Financial Inc. acquired a new position in Pyxis Oncology in the 4th quarter valued at about $35,000. 39.09% of the stock is owned by hedge funds and other institutional investors.
Pyxis Oncology Company Profile
(
Get Free Report)
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
See Also
Before you consider Pyxis Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.
While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access